Neuraly

Neuraly is a clinical-stage biotechnology company focused on developing disease-modifying agents for neurodegenerative disorders. Their focus is on the glial and microglial cells of the brain. Their lead compound, NLY01, is a long-acting, microglia-targeted GLP-1R agonist with promising therapeutic potential for conditions like Parkinson's disease and Alzheimer's disease. It specifically targets microglia, a type of immune cell in the brain, which play a crucial role in neuroinflammation. By modulating microglia activity, NLY01 aims to reduce neuroinflammation and protect neurons from damage. NLY01 has shown promising results in preclinical models, suggesting its potential to slow down or halt the progression of neurodegenerative diseases. It is in phase 2 clinical trials. Neuraly has multiple products in their pipeline for a variety of neurodegenerative disorders.

Jobs: